In Vitro Micropatterned Human Pluripotent Stem Cell Test (µP-hPST) for Morphometric-Based Teratogen Screening

Area of Science:

• Developmental toxicology
• Stem cell biology
• Drug safety assessment

Background:

• Teratogenic chemicals pose risks during pregnancy, necessitating reliable detection methods.
• In vivo animal testing for teratogenicity is limited by inter-species variability and ethical concerns.
• Human pluripotent stem cell (hPSC)-based in vitro assays are crucial for predictive teratogen screening.

Purpose of the Study:

• To develop and validate a novel micropatterned human pluripotent stem cell test (µP-hPST) for identifying teratogenic compounds.
• To establish a simplified morphometric readout and classification rule for teratogen detection using hPSCs.
• To compare the performance of the µP-hPST assay with existing metabolic biomarker-based hPSC assays.

Main Methods:

• Development of the micropatterned human pluripotent stem cell test (µP-hPST) assay.
• Utilizing 30 pharmaceutical compounds for assay validation.
• Implementing a simplified morphometric readout to quantify mesoendoderm pattern changes.
• Generating a two-step classification rule for teratogen identification.

Main Results:

• The optimized µP-hPST assay achieved 97% accuracy, 100% specificity, and 93% sensitivity in classifying 30 compounds.
• The assay successfully identified drugs (Bosentan, Diphenylhydantoin, Lovastatin) misclassified by a metabolic biomarker-based assay.
• µP-hPST demonstrated higher accuracy and sensitivity compared to the Stemina assay.

Conclusions:

• The scalable µP-hPST assay is a highly accurate and sensitive tool for teratogen detection.
• This assay can serve as an independent or complementary method to existing assays, reducing animal use.
• µP-hPST can accelerate early drug discovery and chemical screening for human teratogens.